MGMT and glioblastoma: The PARADIGM-2 trial, which consisted of two parallel phase I studies of olaparib and RT or olaparib and RT plus TMZ in patients with newly diagnosed glioblastoma, used a biomarker-driven approach where MGMT status guides PARP inhibitor dosing intensity with RT, recognizing that patients with unmethylated MGMT promoter derive minimal benefit with TMZ [30].